safety and immunogenicity of a malaria vaccine, plasmodium falciparum ama-1msp-1 chimeric protein formulated in montanide isa 720 in healthy adults一种疟疾疫苗的安全性和免疫原性,恶性疟原虫ama-1msp-1嵌合蛋白制定720年montanide isa在健康的成人.pdfVIP

下载本文档

2
0
约10.73万字
约 14页
2017-09-11 发布于上海
举报
版权申诉

safety and immunogenicity of a malaria vaccine, plasmodium falciparum ama-1msp-1 chimeric protein formulated in montanide isa 720 in healthy adults一种疟疾疫苗的安全性和免疫原性,恶性疟原虫ama-1msp-1嵌合蛋白制定720年montanide isa在健康的成人.pdf

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

safety and immunogenicity of a malaria vaccine, plasmodium falciparum ama-1msp-1 chimeric protein formulated in montanide isa 720 in healthy adults一种疟疾疫苗的安全性和免疫原性,恶性疟原虫ama-1msp-1嵌合蛋白制定720年montanide isa在健康的成人

Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults 1 1 1 1 1 5 3 1 Jinhong Hu , Zhihui Chen , Jun Gu , Mobin Wan , Qian Shen , Marie-Paule Kieny , Jia He , Zhen Li , 2 5 1 1 3 2 4 Qingfeng Zhang , Zarifah Hussain Reed , Yongmei Zhu , Wenjie Li , Yang Cao , Li Qu , Zhifang Cao , 4 4 4 4 2 2 Qiang Wang , Haitao Liu , Xuegong Pan , Xiudong Huang , Dongmei Zhang , Xiangyang Xue , Weiqing Pan2* 1 Changhai Hospital, Second Military Medical University, Shanghai, China, 2 Department of Pathogen Biology and State Key Laboratory of Medical Immunology, Second Military Medical University, Shanghai, China, 3 Department of Statistics, Second Military Medical University, Shanghai, China, 4 Shanghai Wanxing Biopharmaceuticals Co., Ltd., Shanghai, China, 5 Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland Abstract Background: The P. falciparum chimeric protein 2.9 (PfCP-2.9) consisting of the sequences of MSP1-19 and AMA-1 (III) is a malaria vaccine candidate that was found to induce inhibitory antibodies in rabbits and monkeys. This was a phase I randomized, single-blind, placebo-controlled, dose-escalation study to evaluate the safety and immunogenicity of the PfCP- 2.9 formulated with a novel adjuvant Montanide ISA720. Fifty-two subjects were randomly assigned to 4 dose groups of 10 participants, each receiving the test vaccine of 20, 50, 100, or 200 mg respectivel